Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 2/20 | 0.30 |
| ▸ | ARG2 | P78540 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16399053 | 1.00 | DPP4 (0.33) | DPP4DPP8HDAC8HDAC6HDAC1 | |
| SCHEMBL4189545 | 1.00 | DPP4 (0.33) | DPP4DPP8HDAC8HDAC6HDAC1 | |
| SCHEMBL16992402 | 0.76 | CASP3 (0.34) | — | |
| SCHEMBL5560105 | 0.75 | ENPP2 (0.32) | — | |
| SCHEMBL27844467 | 0.75 | HDAC8 (0.34) | DPP4DPP8HDAC8HDAC6HDAC1 | |
| SCHEMBL20213511 | 0.71 | — | — | |
| SCHEMBL26606127 | 0.70 | — | — | |
| SCHEMBL20292091 | 0.70 | CASP3 (0.31) | DPP4DPP8 | |
| SCHEMBL2573230 | 0.70 | — | — | |
| SCHEMBL2912964 | 0.69 | KCNQ3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053449-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-08-21 | — | — | US | disclosed |
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-9714235-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-20160168129-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| EP-3022186-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007219-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2015-01-22 | — | — | WO | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | DPP4 804/4885DPP8 746/4885HDAC8 1751/4885 |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | DPP4 4116/4885DPP8 4789/4885HDAC8 2851/4885 |
| US-20160168129-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | DPP4 804/4885DPP8 746/4885HDAC8 1751/4885 |
| US-10053449-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | ABL1, MAP4K2, DMPK | DPP4 804/4885DPP8 746/4885HDAC8 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.